This is the first time such results have been achieved in both children and adult patients born with a specific type of congenital deafness.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™ Nucleus® Nexa™ System ...

Upgradeable Firmware: The Cochlear™ Nucleus® Nexa™ System features upgradeable firmware on the implant – an industry first, allowing recipients to access future innovation through firmware ...

The Nucleus Nexa System builds upon Cochlear's industry-leading portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of ...

Youth with congenital deafness treated with gene therapy showed better progress on certain hearing measures than counterparts ...

Cochlear Implantation and Vestibular Function Publication Trend The graph below shows the total number of publications each year in Cochlear Implantation and Vestibular Function.

Cochlear amplifier: A process driven by outer hair cell motility that enhances the sensitivity and selectivity of auditory responses.

Let's see what the broker is saying about this blue chip. The post What are Cochlear shares worth according to Macquarie?

New research from Professor Guillermo Ameer’s team shows how a shape change of a cell’s nucleus can trigger regenerative ...